Quantitative evaluation of CK19 maker expression in blood samples of people with leukemia by Real Time PCR

Subject Areas : genetics

sara tajer ¹ , azadeh mohammadgholi ² , ardeshir hesampour ³

1 - ,Department biology,faculty of basic science Islamic Azad University, Central Tehran Branch,tehran.iran
2 - ,Department biology,faculty of basic science Islamic Azad University, Central Tehran Branch,tehran.iran
3 - department biology, faculty of basic science islamic azad university, central tehran branch, tehran, iran

Received: 2019-02-21 Accepted : 2019-10-14 Published : 2018-08-23

Keywords: biomarker, Leukemia, CK19, Chronic myelogenous leukemia,

Abstract :

Introduction: Leukemia makes up about 8% of all cancers. Understanding the epidemiology of leukemia is very effective in planning for this cancer. Chronic Myeloid Leukemia (CML) is a malignant clonal disorder of hematopoietic stem cells which results in increase of myeloid cells, erythroid cells and platelets in the peripheral blood and hyperplasia in bone marrow. Cytokeratin 19 (CK19) is a part of the cytoskeleton of epithelial cells. It is the smallest member of the Cytokeratin family. CK19 is known as a marker of epithelial cells. In the present study, we examined the CK19 expression levels in de novo CML and investigated correlation between altered expression of CK19 with patients’ clinical characteristics. Methods: 50 patients with Leukemia (CML type) were compared with 50 healthy controls. After taking blood samples and extracting total RNA, cDNA was synthesized and examined by Real-time RT-PCR technique. Results:Study of CK19 gene expression in leukemia cells compared to control samples by Real time RT-PCR .In the leukemia sample, the expression of the CK19 gene was evaluated. The results showed that expression of CK19 gene did not increase significantly in the patient group Conclusions: Investigation on the presence of Cytokeratin-19 biomarker in the early stages of disease could be a suitable prognostic factor in blood of the patients. Study on a larger number of patients with more biomarkers with the predictive and/or prognostic value should be considered in the future studies.